SR Edit Staff, Author at Sleep Review

FDA Grants Priority Review to Takeda’s Oveporexton for Narcolepsy Type 1

Feb 11, 2026 |

The investigational oral OX2R-selective agonist is designed to restore orexin signaling; the FDA has set a target action date for the third quarter of 2026.

Ambulatory Monitoring to Release FDA-Cleared Smartwatch-Style Actigraph

Feb 10, 2026 |

The new Sleep Watch actigraph features cloud-based software and over-the-air updates, offering sleep estimation for children and adults.

Amneal Receives FDA Approval for Sodium Oxybate Oral Solution

Feb 9, 2026 |

The approval allows Amneal to offer a generic alternative for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients, expanding access to this standard of care therapy.